|
Abnormality of the voice
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Adenoma
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Partial (1%-10%) and extensive (10%-100%) DLC-1 promoter methylations were observed in 10% and 0% of normal mucosa, 46% and 14% of adenomas, and 60% and 36% of CRCs, respectively.
|
23509688 |
2013 |
|
Adult Burkitt Lymphoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
DLC-1 expression was not detectable in two human BL cell lines, Raji and Daudi, by reverse transcription-PCR.
|
20882354 |
2011 |
|
Adult Hodgkin Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Furthermore, DLEC1 was specifically methylated in the sera of 3/13 (23%) Hodgkin lymphoma patients.
|
23050586 |
2012 |
|
Adult Liver Carcinoma
|
0.070 |
GeneticVariation
|
disease |
BEFREE |
The deleted in liver cancer (DLC-1) gene at chromosome 8p21-22 is altered mainly by genomic deletion or aberrant promoter methylation in a large number of human cancers such as breast, liver, colon and prostate and is known to have an inhibitory effect on breast and liver tumor cell growth.
|
14661059 |
2004 |
|
Adult Liver Carcinoma
|
0.070 |
Biomarker
|
disease |
BEFREE |
DLC-1 may be a tumor suppressor gene in liver cancer as well as in other cancers.
|
9605766 |
1998 |
|
Adult Liver Carcinoma
|
0.070 |
Biomarker
|
disease |
BEFREE |
DLC-1 (deleted in liver cancer) gene is frequently deleted in hepatocellular carcinoma.
|
12813468 |
2003 |
|
Adult Liver Carcinoma
|
0.070 |
Biomarker
|
disease |
BEFREE |
The DLC-1 gene encoding a regulator of the Rho family of small GTPases is altered in breast, prostate, colon, and liver cancer and has several characteristics of a tumor suppressor gene.
|
12792785 |
2003 |
|
Adult Liver Carcinoma
|
0.070 |
GeneticVariation
|
disease |
BEFREE |
We investigated the expression and deletion of DLC-1 (frequently deleted in liver cancer gene), first reported in 1998 and having a high homology with rat p122RhoGAP in hepatocellular carcinoma (HCC).
|
11118037 |
2000 |
|
Adult Liver Carcinoma
|
0.070 |
GeneticVariation
|
disease |
BEFREE |
Further, the miRNA-target gene network analysis displayed that the deleted in liver cancer (DLC-1) gene, an important negative regulator for cell motility, was potentially targeted by several differentially expressed miRNAs in HBc-introduced cells.
|
28982593 |
2018 |
|
Adult Liver Carcinoma
|
0.070 |
Biomarker
|
disease |
BEFREE |
The SH2 domain in tensin family member c-ten requires R474 to bind a RhoGAP called DLC-1 (deleted in liver cancer).
|
19826001 |
2009 |
|
Adult Lymphoma
|
0.020 |
PosttranslationalModification
|
disease |
BEFREE |
Thus, methylation-mediated silencing of DLEC1 plays an important role in multiple lymphomagenesis, and may serve as a non-invasive tumor marker for lymphoma diagnosis.
|
23050586 |
2012 |
|
Adult Lymphoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our findings suggest that DLC-1 may play an important role in lymphoma by acting as a bona fide new tumor suppressor gene.
|
20882354 |
2011 |
|
Allergic rhinitis (disorder)
|
0.010 |
Biomarker
|
disease |
BEFREE |
DLC (i.v.), given after an allergen challenge, improved Th1 cytokines level and restrained Th2 responses alleviating the symptoms of AR.
|
26155922 |
2015 |
|
Arteriosclerosis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We found increased expression of DLC-1 in stiffness-associated diseases like atherosclerosis and pulmonary arterial hypertension.
|
30231995 |
2018 |
|
Atherosclerosis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We found increased expression of DLC-1 in stiffness-associated diseases like atherosclerosis and pulmonary arterial hypertension.
|
30231995 |
2018 |
|
Benign Prostatic Hyperplasia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We found that DLEC1 was highly expressed in normal prostate tissues, normal prostatic epithelium cell line (RWPE-1), and benign prostatic hyperplasia cell line (BPH-1), but frequently downregulated by promoter methylation in PrCa cell lines.
|
25648635 |
2015 |
|
Breast Carcinoma
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
Detecting the changes of the expression of DLC-1 in the breast carcinoma may contribute to earlier auxiliary diagnosis of invasiveness, metastasis and recrudescence.
|
22799310 |
2012 |
|
Breast Carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
Furthermore, introduction of the DLC-1 cDNA abolished the in vivo tumorigenicity in nude mice, suggesting that the DLC-1 gene plays a role in breast cancer by acting as a bona fide tumor suppressor gene.
|
12545165 |
2003 |
|
Breast Carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
These findings are consistent with a possible tumour suppressor function of DLEC1 in breast cancer.
|
20530412 |
2010 |
|
Breast Carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
Our results indicate a role of DLC-1 in BC carcinogenesis.
|
12759748 |
2003 |
|
Breast Carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
The RhoGAP protein DLC-1 functions as a metastasis suppressor in breast cancer cells.
|
16024604 |
2005 |
|
Breast Carcinoma
|
0.060 |
PosttranslationalModification
|
disease |
BEFREE |
To determine the implication of aberrant methylation, one of the most frequent mechanisms of silencing the tumor suppressor or cancer-related genes, we examined the methylation status of DLC-1 promoter region in breast cancer cell lines and primary breast tumors.
|
15201975 |
2004 |
|
Burkitt Lymphoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
DLC-1 expression was not detectable in two human BL cell lines, Raji and Daudi, by reverse transcription-PCR.
|
20882354 |
2011 |
|
Carcinogenesis
|
0.090 |
Biomarker
|
phenotype |
BEFREE |
The smallest region homozygously deleted in 3p21.3T was flanked by D3S1298 and NL1-024 (D3S4285), excluding DLEC1 and MYD88 as candidate TSGs involved in cervical carcinogenesis.
|
12771950 |
2003 |